PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsEtoposide
Etoposide
Etopophos, Etoposide (etoposide) is a small molecule pharmaceutical. Etoposide was first approved as Vepesid on 1983-11-10. It is used to treat brain neoplasms, ewing sarcoma, histiocytosis, kaposi sarcoma, and lung neoplasms amongst others in the USA. The pharmaceutical is active against DNA topoisomerase 2-alpha.
Download report
Favorite
BMS
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
neoplasmsD009369
respiratory tract diseasesD012140
nervous system diseasesD009422
urogenital diseasesD000091642
hemic and lymphatic diseasesD006425
endocrine system diseasesD004700
immune system diseasesD007154
Trade Name
FDA
EMA
Etopophos, Etoposide (discontinued: Etopophos, Etoposide, Toposar, Vepesid)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Etoposide
Tradename
Company
Number
Date
Products
VEPESIDCordenPharmaN-018768 DISCN1983-11-10
1 products, RLD
VEPESIDStrides Pharma GlobalN-019557 DISCN1986-12-30
2 products, RLD
Hide discontinued
Etoposide phosphate
Tradename
Company
Number
Date
Products
ETOPOPHOS PRESERVATIVE FREECHEPLAPHARM ArzneimittelN-020457 RX1996-05-17
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
etopophosNew Drug Application2023-11-13
etoposideANDA2024-10-03
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01C: Plant alkaloids and other natural products, antineoplastic drugs
— L01CB: Podophyllotoxin derivatives, antineoplastic drugs
— L01CB01: Etoposide
HCPCS
Code
Description
J8560
Etoposide; oral, 50 mg
J9181
Injection, etoposide, 10 mg
Clinical
Clinical Trials
1869 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223—C85.911———2
Hodgkin diseaseD006689—C8111———2
Multiple myelomaD009101—C90.0—1———1
Plasma cell neoplasmsD054219———1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938—C951————1
Hematologic neoplasmsD019337——1————1
Non-hodgkin lymphomaD008228—C85.91————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameEtoposide
INNetoposide
Description
Etoposide is a beta-D-glucoside, a furonaphthodioxole and an organic heterotetracyclic compound. It has a role as an antineoplastic agent and a DNA synthesis inhibitor. It is functionally related to a podophyllotoxin and a 4'-demethylepipodophyllotoxin.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O
Identifiers
PDB—
CAS-ID33419-42-0
RxCUI—
ChEMBL IDCHEMBL44657
ChEBI ID4911
PubChem CID36462
DrugBankDB00773
UNII ID6PLQ3CP4P3 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
TOP2B
TOP2B
Organism
Homo sapiens
Gene name
TOP2B
Gene synonyms
NCBI Gene ID
Protein name
DNA topoisomerase 2-beta
Protein synonyms
antigen MLAA-44, DNA topoisomerase II, 180 kD, DNA topoisomerase II, beta isozyme, topo II beta, topoisomerase (DNA) II beta 180kDa, topoisomerase II beta, topoisomerase IIb, U937 associated antigen
Uniprot ID
Mouse ortholog
Top2b (21974)
DNA topoisomerase 2-beta (Q7TQG4)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Etoposide
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 71,048 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
61,864 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use